Cellosaurus ML-1 [Human thyroid carcinoma] (CVCL_H525)

Cell line name ML-1 [Human thyroid carcinoma]
Synonyms ML1
Accession CVCL_H525
Resource Identification Initiative To cite this cell line use: ML-1 [Human thyroid carcinoma] (RRID:CVCL_H525)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: ~4-7 days (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Thyroid gland follicular carcinoma (NCIt: C8054)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; PubMed=18713817

Markers:
AmelogeninX
CSF1PO10,14
D13S31710
D16S53910,12
D18S5118
D21S1131.2,33.2
D3S135815
D5S81812,13
D7S82010
D8S117910,13
FGA22,25
TH018
TPOX11
vWA17,18
Publications

PubMed=10794546; DOI=10.1007/s001090000085
Schonberger J., Bauer J., Spruss T., Weber G., Chahoud I., Eilles C., Grimm D.
Establishment and characterization of the follicular thyroid carcinoma cell line ML-1.
J. Mol. Med. 78:102-110(2000)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections DSMZ; ACC-464
Cell line databases/resources CCLE; ML1_THYROID
Cosmic-CLP; 1240178
GDSC; 1240178
LINCS_LDP; LCL-1679
Biological sample resources BioSample; SAMN03473557
Gene expression databases GEO; GSM887327
GEO; GSM888403
GEO; GSM1670115
Polymorphism and mutation databases Cosmic; 1239975
Cosmic; 2054099